Memory B Cell Compartment David J

Total Page:16

File Type:pdf, Size:1020Kb

Memory B Cell Compartment David J Development and Maintenance of a B220− Memory B Cell Compartment David J. Driver, Louise J. McHeyzer-Williams, Melinda Cool, Daniel B. Stetson and Michael G. McHeyzer-Williams This information is current as of September 29, 2021. J Immunol 2001; 167:1393-1405; ; doi: 10.4049/jimmunol.167.3.1393 http://www.jimmunol.org/content/167/3/1393 Downloaded from References This article cites 63 articles, 29 of which you can access for free at: http://www.jimmunol.org/content/167/3/1393.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 29, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Development and Maintenance of a B220؊ Memory B Cell Compartment1 David J. Driver, Louise J. McHeyzer-Williams, Melinda Cool, Daniel B. Stetson,2 and Michael G. McHeyzer-Williams3 We have recently demonstrated that a novel somatically mutated B220؊ memory B cell subset rapidly dominates the secondary immune response to (4-hydroxy-3-nitrophenyl) acetyl (NP). Upon adoptive transfer with Ag, B220؉NP؉ memory B cells produce large numbers of B220؊NP؉ B cells that can rapidly differentiate into plasma cells. Therefore, it is not clear whether the novel B220؊ memory compartment is a consequence of secondary Ag challenge or whether it develops as a stable memory subset after initial Ag challenge. In this study, we demonstrate the gradual emergence of B220؊NP؉ B cells in the spleen to maximal numbers ,wk after initial Ag exposure. Like their B220؉ counterparts, the B220؊ B cells initially appear unmutated at days 5–7; however 3 the majority rapidly accumulate affinity increasing mutations by days 9–14 of the primary immune response. More extensive cell Downloaded from surface phenotype (GL7؊BLA-1؊CD24؊CD43؉) argues strongly against germinal center localization and direct analysis in situ places a cohort of B220؊CD11b؉NP؉ B cells in the red pulp of the spleen and not in the MZs. These data provide direct evidence for the development of B220؊ memory B cells as a unique cellular consequence of primary Ag exposure. The cellular dynamics and molecular attributes of these unique memory B cells suggest they are distinct cellular products of the germinal center reaction in the primary response and are maintained long-term in the spleen and bone marrow. The Journal of Immunology, 2001, 167: 1393–1405. http://www.jimmunol.org/ cell memory is characterized by the rapid appearance B220Ϫ memory B cell subset emerges following secondary chal- of high-affinity Abs in response to secondary Ag chal- lenge as a major cellular component of the Ag-specific memory B B lenge. This accelerated humoral recall response is due to cell response and contributes significantly to the rapid appearance the expansion of affinity-matured memory response precursors of high-affinity Ab. and their rapid differentiation into plasma cells (1). We have Although the B220Ϫ subset clearly emerges upon secondary recently identified two distinct subsets of isotype-switched challenge, it is not known how this novel subset of B cell memory (IgMϪIgDϪIgGϩ) and somatically mutated memory B cells that develops. Although our previous work provides some indication by guest on September 29, 2021 do not secrete Ab, but can give rise to plasma cells upon adoptive for both subsets of specific memory responders before secondary transfer with Ag (2). One of these subsets expresses high levels of Ag challenge, cell numbers are very low at this point and are not the B lineage marker B220 (the B cell isoform of CD45R; RA3- significantly greater than the adjuvant-only controls (2). In addi- 6B2 binding) and CD19. These B220ϩ memory B cells expand to tion, adoptive transfer experiments in this study demonstrate a hi- peak levels by day 4 following secondary Ag challenge and persist erarchical parent-progeny relationship in which B220ϩ memory B in the spleen for at least 6 wk. Although the second memory subset cells produce nonsecreting B220Ϫ B cell intermediates that then does express CD45R (30-F11 binding), they do not express the B Ϫ cell isoform B220 or CD19. These novel B220Ϫ memory respond- give rise to plasma cells. This pattern suggests that the B220 ers emerge in the spleen with kinetics similar to those of the population seen to expand upon secondary challenge could actu- ϩ B220ϩ subset, but persist long term at much higher frequencies. ally be a product of the B220 memory B cell subset. Thus, ques- Ϫ This unique B220Ϫ memory subset also comprises Ͼ95% of the tions regarding the development of these unique B220 memory B Ag-specific B cells in the bone marrow (BM).4 Thus, a novel cells cannot be answered simply by extrapolation from our previ- ous findings on memory responders and their progeny. Since both memory B cell subsets express somatically mutated Ig, it is likely that their precursors originate in the germinal center Department of Immunology, Duke University Medical Center, Durham, NC 27710 (GC) reaction during the primary response (3, 4). Although there Received for publication September 5, 2000. Accepted for publication May 16, 2001. have been reports of somatic mutation in the absence of GC for- The costs of publication of this article were defrayed in part by the payment of page mation in lymphotoxin ␣- (5) and Lyn-deficient animals (6), so- charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. matic mutation in both cases was reported only after tertiary im- 1 This work was supported by grants from the National Institutes of Health (AI47231 munization, and GC have subsequently been observed in the and AI40215) and an Arthritis Foundation Biomedical Grant. mesenteric lymph nodes of the lymphotoxin ␣Ϫ/Ϫ mice (7). The 2 Current address: Departments of Medicine and Microbiology/Immunology, Howard greater weight of evidence supports the GC microenvironment as Hughes Medical Institute, University of California, San Francisco, CA 94143. the site of somatic mutation and affinity-based selection in the 3 Address correspondence and reprint requests to Dr. Michael McHeyzer-Williams, Department of Immunology, Duke University Medical Center, Box 3010, Durham, development of B cell memory (8–14). Therefore, we propose that NC 27710. E-mail address: [email protected] the B220Ϫ memory B cells either 1) develop in the GC during the 4 Abbreviations used in this paper: BM, bone marrow; GC, germinal center; PI, pro- primary response, 2) are the progeny of primary response GC B pidium iodide; NP, (4-hyroxy-3-nitrophenyl)acetyl; KLH, keyhole limpet hemocya- ϩ nin; HSA, heat- stable Ag; PI, propidium iodide; PNA, peanut agglutinin; MZ, mar- cells, or 3) are the progeny of B220 memory B cells and arise ginal zone; TR, Texas Red; APC, allophycocyanin; CR, complement receptor. only as a consequence of Ag recall. Copyright © 2001 by The American Association of Immunologists 0022-1767/01/$02.00 1394 DEVELOPMENT OF Ag-SPECIFIC B CELL MEMORY To address this issue directly, we used the Th cell-dependent F11), anti-CD19 (FITC-1D3), anti-CD21 (FITC-7G6), and anti-CD22 response to the hapten 4-hydroxy-3-nitrophenyl acetyl (NP) in (FITC-Cy34.1). Cells were washed twice in FACS wash and resuspended ␮ C57BL/6 mice (15). The primary response to NP in these mice is in FACS wash containing 2 g/ml propidium iodide (PI) for analysis. Cells were analyzed using a modified dual laser FACStarPlus (BD Im- dominated by B cells that express the VH186.2 H chain and the munocytometry Systems, Mountain View, CA) capable of simultaneous ␭ ϩ VL 1 L chain genes (16–19). NP GC B cells reach maximum seven-parameter acquisition and fluorescence overlap compensation across numbers by day 7 of the primary splenic response and persist at lasers. Files were acquired using CellQuest software (BD Biosciences, these levels for at least 3 wk in the spleen (16). Somatic hyper- Mountain View, CA), analyzed using FlowJo software (Tree Star, San Carlos, CA), and displayed as 5% probability contours with outliers. mutation has been observed as early as day 6 after priming and progressively increases for the duration of the GC reaction (16, Single-cell mutational analysis 20). GC B cells bind high levels of peanut agglutinin (PNA) (21) cDNA synthesis. Single NP-specific B cells were sorted according to phe- and express B220 (22), GL7 (23), CD24 (heat-stable Ag (HSA)) notype using a five-color flow cytometry strategy with an automatic cell (24), and BLA-1 (25), allowing them to be distinguished from dispensing unit attached to the FACStarPlus using CloneCyt software (BD ϩ Ϫ ϩ ␮ plasma cells, which are characterized as being B220 / CD138 , Biosciences). Individual cells were sorted into 5 l of an oligo(dT)-primed ϩ cDNA reaction mixture (4 U/ml murine leukemia virus-reverse transcrip- and CD43 (26, 27). Affinity-matured plasma cells are also ob- tase (Life Technologies, Rockville, MD) with recommended reverse tran- served to persist at very low frequencies in the BM (28, 29), high- scriptase buffer, 0.5 nM spermidine (Sigma Chemical), 100 ␮g/ml BSA lighting the spleen and BM as two main reservoirs for long-lived (Boehringer Mannheim, Indianapolis, IN), 10 ng/␮l oligo(dT) (BD Bio- Ag-specific B cells.
Recommended publications
  • SAHLGRENSKA AKADEMIN Thymic Studies
    Göteborg, 2019 Thymic studies Investigations into the effects of childhood thymectomy, and characterization of thymic B cells and Hassall's corpuscles Akademisk avhandling Som för avläggande av medicine doktorsexamen vid Sahlgrenska akademin, Göteborgs universitet kommer att offentligen försvaras i föreläsningssalen våning 3, Guldhedsgatan 10A, Göteborg Tisdagen den 14e maj, klockan 13.00 av Christina Lundqvist Fakultetsopponent: Professor Ludger Klein Ludwig-Maximilians-Universität, Tyskland Avhandlingen baseras på följande delarbeten I. Gudmundsdottir J*, Lundqvist C*, Ijspeert H, van der Slik E, Óskarsdóttir S, Lindgren S, Lundberg V, Berglund M, Lingman-Framme J, Telemo E, van der Burg M, Ekwall O. T-cell receptor sequencing reveals decreased diversity 18 years after early thymectomy. J Allergy Clin Immunol. 2017 Dec;140(6):1743- 1746.e7. doi: 10.1016/j.jaci.2017.08.002. Epub 2017 Sep 1. * These authors contributed equally to this work. II. Lundqvist C*, Camponeschi A*, Visentini M, Telemo E, Ekwall O‡, Mårtensson IL‡. Switched CD21-/low B cells with an antigen-presenting phenotype in the infant thymus. J Allergy Clin Immunol. 2018 Nov 30. pii: S0091-6749(18)31721- 4. doi: 10.1016/j.jaci.2018.11.019. * These authors contributed equally to this work. ‡ These authors contributed equally to this work. III. Lundqvist C, Lindgren S, Cheuk S, Lundberg V, Berglund M, Thörn K, Telemo E, Ekwall O. Characterization of Hassall's corpuscles in the human thymus. Manuscript SAHLGRENSKA AKADEMIN INSTITUTIONEN FÖR MEDICIN Göteborg, 2019 Thymic studies Investigations into the effects of childhood thymectomy, and characterization of thymic B cells and Hassall's corpuscles Christina Lundqvist Avdelningen för reumatologi och inflammationsforskning, Institutionen för medicin, Sahlgrenska akademin, Göteborgs universitet Abstract This thesis focuses on the human thymus, a primary lymphoid organ responsible for the maturation of T cells.
    [Show full text]
  • B Cells + Interaction
    Human B Cell Activation by Autologous NK Cells Is Regulated by CD40-CD40 Ligand Interaction: Role of Memory B Cells and CD5 + B Cells This information is current as of October 2, 2021. Isaac R. Blanca, Earl W. Bere, Howard A. Young and John R. Ortaldo J Immunol 2001; 167:6132-6139; ; doi: 10.4049/jimmunol.167.11.6132 http://www.jimmunol.org/content/167/11/6132 Downloaded from References This article cites 45 articles, 17 of which you can access for free at: http://www.jimmunol.org/content/167/11/6132.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on October 2, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2001 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Human B Cell Activation by Autologous NK Cells Is Regulated by CD40-CD40 Ligand Interaction: Role of Memory B Cells and CD5؉ B Cells Isaac R. Blanca,*† Earl W. Bere,* Howard A.
    [Show full text]
  • Advanced Laboratory Studies for Primary Immunodeficiency Disorders
    4813: Problem-based Learning Workshop Advanced Laboratory studies for Primary Immunodeficiency Disorders Moderator: Richard Wasserman, MD, PhD Discussion Leader: Roshini Abraham, PhD ● Understand B cell flow analysis in CVID (PBL case) HUMAN PERIPHERAL B CELL DIFFERENTIATION Marginal zone B cells Bone marrow Immature B cells Transitional B cells Naïve B cells Memory B cells Plasmablasts Periphery MARKERS FOR PERIPHERAL B CELL SUBSETS - CURRENT Total B cells: CD19 and/or CD20 Transitional B cells: CD19+CD38+IgM+ Total IgM+ B cells: CD19+IgM+ (includes naïve B cells) Memory B cells: CD19+CD27+ switched memory B cells: CD19+CD27+IgM-IgD- marginal zone B cells: CD19+CD27+IgM+IgD+ IgM-only memory B cells: CD19+CD27+IgM+IgD- Plasmablasts: CD19+CD38+IgM- CD21+ B cells: CD19+CD21+ CD21- B cells: CD19+CD21- ● With newer information, more suitable cellular markers are available for accurate identification of transitional B cells and plasmablasts, in particular, but also for naïve B cells NEWER B CELL MARKERS FOR B CELL SUBSET QUANTITATION Total B cells and B cell subsets can be quantitated in blood using multicolor flow cytometry: Total B cells: CD45+CD19+20+ For B cell subset analysis, the gating strategy uses CD45+19+20+/- (depending on the subset being studied), thus these markers are not specifically repeated in the panel below:- Transitional B cells: T1: CD24hi38hi10+27-21lowIgM+++ T2: CD24hi38hi10+27-21int IgM+++ Naïve B cells: IgM+IgD+27-38-21+++ Memory B cells: Marginal zone B cells: CD27+IgM+IgD+ IgM-only memory: CD27+IgM+IgD- IgD-only
    [Show full text]
  • Vaccine Immunology Claire-Anne Siegrist
    2 Vaccine Immunology Claire-Anne Siegrist To generate vaccine-mediated protection is a complex chal- non–antigen-specifc responses possibly leading to allergy, lenge. Currently available vaccines have largely been devel- autoimmunity, or even premature death—are being raised. oped empirically, with little or no understanding of how they Certain “off-targets effects” of vaccines have also been recog- activate the immune system. Their early protective effcacy is nized and call for studies to quantify their impact and identify primarily conferred by the induction of antigen-specifc anti- the mechanisms at play. The objective of this chapter is to bodies (Box 2.1). However, there is more to antibody- extract from the complex and rapidly evolving feld of immu- mediated protection than the peak of vaccine-induced nology the main concepts that are useful to better address antibody titers. The quality of such antibodies (e.g., their these important questions. avidity, specifcity, or neutralizing capacity) has been identi- fed as a determining factor in effcacy. Long-term protection HOW DO VACCINES MEDIATE PROTECTION? requires the persistence of vaccine antibodies above protective thresholds and/or the maintenance of immune memory cells Vaccines protect by inducing effector mechanisms (cells or capable of rapid and effective reactivation with subsequent molecules) capable of rapidly controlling replicating patho- microbial exposure. The determinants of immune memory gens or inactivating their toxic components. Vaccine-induced induction, as well as the relative contribution of persisting immune effectors (Table 2.1) are essentially antibodies— antibodies and of immune memory to protection against spe- produced by B lymphocytes—capable of binding specifcally cifc diseases, are essential parameters of long-term vaccine to a toxin or a pathogen.2 Other potential effectors are cyto- effcacy.
    [Show full text]
  • B-Cell Development, Activation, and Differentiation
    B-Cell Development, Activation, and Differentiation Sarah Holstein, MD, PhD Nov 13, 2014 Lymphoid tissues • Primary – Bone marrow – Thymus • Secondary – Lymph nodes – Spleen – Tonsils – Lymphoid tissue within GI and respiratory tracts Overview of B cell development • B cells are generated in the bone marrow • Takes 1-2 weeks to develop from hematopoietic stem cells to mature B cells • Sequence of expression of cell surface receptor and adhesion molecules which allows for differentiation of B cells, proliferation at various stages, and movement within the bone marrow microenvironment • Immature B cell leaves the bone marrow and undergoes further differentiation • Immune system must create a repertoire of receptors capable of recognizing a large array of antigens while at the same time eliminating self-reactive B cells Overview of B cell development • Early B cell development constitutes the steps that lead to B cell commitment and expression of surface immunoglobulin, production of mature B cells • Mature B cells leave the bone marrow and migrate to secondary lymphoid tissues • B cells then interact with exogenous antigen and/or T helper cells = antigen- dependent phase Overview of B cells Hematopoiesis • Hematopoietic stem cells (HSCs) source of all blood cells • Blood-forming cells first found in the yolk sac (primarily primitive rbc production) • HSCs arise in distal aorta ~3-4 weeks • HSCs migrate to the liver (primary site of hematopoiesis after 6 wks gestation) • Bone marrow hematopoiesis starts ~5 months of gestation Role of bone
    [Show full text]
  • B Cell Responses Against Influenza Viruses
    viruses Review B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat Jenna J. Guthmiller 1,* , Henry A. Utset 1 and Patrick C. Wilson 1,2 1 Section of Rheumatology, Department of Medicine, University of Chicago, Chicago, IL 60637, USA; [email protected] (H.A.U.); [email protected] (P.C.W.) 2 Committee on Immunology, University of Chicago, Chicago, IL 60637, USA * Correspondence: [email protected] Abstract: Antibodies are critical for providing protection against influenza virus infections. However, protective humoral immunity against influenza viruses is limited by the antigenic drift and shift of the major surface glycoproteins, hemagglutinin and neuraminidase. Importantly, people are exposed to influenza viruses throughout their life and tend to reuse memory B cells from prior exposure to generate antibodies against new variants. Despite this, people tend to recall memory B cells against constantly evolving variable epitopes or non-protective antigens, as opposed to recalling them against broadly neutralizing epitopes of hemagglutinin. In this review, we discuss the factors that impact the generation and recall of memory B cells against distinct viral antigens, as well as the immunological limitations preventing broadly neutralizing antibody responses. Lastly, we discuss how next-generation vaccine platforms can potentially overcome these obstacles to generate robust and long-lived protection against influenza A viruses. Keywords: influenza viruses; humoral immunity; broadly neutralizing antibodies; imprinting; Citation: Guthmiller, J.J.; Utset, H.A.; hemagglutinin; germinal center; plasma cells Wilson, P.C. B Cell Responses against Influenza Viruses: Short-Lived Humoral Immunity against a Life-Long Threat. Viruses 2021, 13, 1.
    [Show full text]
  • Evasion of Affinity-Based Selection in Germinal Centers by Epstein–Barr Virus LMP2A
    Evasion of affinity-based selection in germinal centers by Epstein–Barr virus LMP2A Takeharu Minamitania,1, Teruhito Yasuia,1,2, Yijie Mab, Hufeng Zhoub, Daisuke Okuzakic, Chiau-Yuang Tsaia, Shuhei Sakakibaraa, Benjamin E. Gewurzb, Elliott Kieffb,2, and Hitoshi Kikutania,2 aDepartment of Molecular Immunology, Research Institute for Microbial Diseases, World Premier International Immunology Frontier Research Center, Osaka University, Suita, Osaka 565-0871, Japan; bDivision of Infectious Disease, Department of Medicine, Microbiology and Immunobiology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA 02115; and cDNA-chip Development Center for Infectious Diseases, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan Contributed by Elliott Kieff, July 27, 2015 (sent for review May 1, 2015) Epstein–Barr virus (EBV) infects germinal center (GC) B cells and B-cell development or augments the differentiation and acti- establishes persistent infection in memory B cells. EBV-infected B vation of antigen-driven B cells (9, 10, 14–16). cells can cause B-cell malignancies in humans with T- or natural In the peripheral blood of persistently infected people, EBV − killer-cell deficiency. We now find that EBV-encoded latent mem- resides exclusively in IgD memory B cells (17). However, in ton- brane protein 2A (LMP2A) mimics B-cell antigen receptor (BCR) signal- sils, EBV is found not only in memory B cells but also in GC and + ing in murine GC B cells, causing altered humoral immune responses IgD resting B cells in which EBNA1, LMP1, and LMP2A are and autoimmune diseases. Investigation of the impact of LMP2A on expressed (17, 18).
    [Show full text]
  • An Overview of B Cells – from Discovery to Therapy Mini Review
    An Overview of B Cells – from Discovery to Therapy Mini Review Immunology In the past two decades, significant advances have been made in B cell biology. These critical immune cells remain an active area of research particularly because disruption of B cell development or function results in a number of autoimmune diseases and malignancies. In addition to producing antibodies, B cells are professional antigen presenting cells that can present antigens to T cells to generate effective immune responses. B cells are however, a heterogeneous population of cells at different stages of maturation along the lineage, each with unique functional properties. This mini-review provides a brief history of the discovery of B cells, as well as describes the characteristics of each B cell lineage and the processes of B cell development, maturation and activation. Finally, we highlight the application of B cell biology in the development of novel therapeutics for the treatment of B cell mediated diseases. Contents 1. A brief history of the discovery of B cells 2. B cell development and maturation 3. B cell activation and the humoral immune response 4. B cells as therapeutic targets 1. A brief history of the discovery of B cells B cells are an integral part of the adaptive immune response. They represent a distinct lineage, with separate and unique functions from T cells. In addition to producing antibodies, they perform critical immune functions such as generating immunological memory, antigen presentation and regulatory cytokine production. Our current understanding of B cell biology was initiated in 1965 with a landmark study by Max Cooper and Robert Good.
    [Show full text]
  • Pathogen Manipulation of B Cells: the Best Defence Is a Good Offence
    REVIEWS Pathogen manipulation of B cells: the best defence is a good offence Katharina Nothelfer1–3, Philippe J. Sansonetti1,2,4 and Armelle Phalipon1,2 Abstract | B cells have long been regarded as simple antibody production units, but are now becoming known as key players in both adaptive and innate immune responses. However, several bacteria, viruses and parasites have evolved the ability to manipulate B cell functions to modulate immune responses. Pathogens can affect B cells indirectly, by attacking innate immune cells and altering the cytokine environment, and can also target B cells directly, impairing B cell-mediated immune responses. In this Review, we provide a summary of recent advances in elucidating direct B cell–pathogen interactions and highlight how targeting this specific cell population benefits different pathogens. pattern recognition receptors 4–6 (FIG. 1) Immunoglobulin B cells are essential components of the adaptive immune general (PRRs) . The A large, Y‑shaped protein that system, and they were first defined and distinguished activation of several B cell clones (termed polyclonal is produced by B cells. from T cells almost 50 years ago1. Both B cells and T cells B cell activation) and their subsequent differentiation Immunoglobulins exist in a recognize pathogens with antigen-specific receptors, into short-lived plasma cells results in the production membrane-bound form as B cell receptors or are secreted but they differ in their developmental pathways and of low-specificity antibodies, which are generally asso- as antibodies. functions during infections. T cells differentiate in the ciated with the beneficial effects of an early weakening thymus and orchestrate immune responses as CD4+ of infections7.
    [Show full text]
  • 691.Full.Pdf
    Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis This information is current as Rui Li, Ayman Rezk, Mathab Ghadiri, Felix Luessi, Frauke of September 29, 2021. Zipp, Hulun Li, Paul S. Giacomini, Jack Antel and Amit Bar-Or J Immunol 2017; 198:691-698; Prepublished online 14 December 2016; doi: 10.4049/jimmunol.1601649 Downloaded from http://www.jimmunol.org/content/198/2/691 Supplementary http://www.jimmunol.org/content/suppl/2016/12/14/jimmunol.160164 Material 9.DCSupplemental http://www.jimmunol.org/ References This article cites 32 articles, 8 of which you can access for free at: http://www.jimmunol.org/content/198/2/691.full#ref-list-1 Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision by guest on September 29, 2021 • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts Errata An erratum has been published regarding this article. Please see next page or: /content/202/7/2172.full.pdf The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2017 by The American Association of Immunologists, Inc. All rights reserved.
    [Show full text]
  • B Cells, Ig, Aging and Inflammation Bonnie B. Blomberg
    Immunology of aging #1: Why older adults are at increased risk of vaccine-preventable diseases Bonnie B. Blomberg Dept. of Microbiology and Immunology U Miami Miller School of Medicine Immunization in the elderly World Health Organization March 22-23, 2017 WHO Objectives: 1) Discuss the immunologic basis for why susceptibility to vaccine preventable diseases increases with age. 2) Discuss the immunologic basis for why response to vaccination decreases with age 3) Present possible mechanisms for these effects with our data on the molecular and cellular mechanisms affecting B cells and chronic inflammation in the elderly Franco Ferracci, Ryan Thomas, Acknowledgements Nick Mendez Mitch Phillips, John Ryan, Robert Schwartz, Family Medicine Sandra Chen, Daniela Frasca Env. Health & Safety Alain Diaz Bali Pulendran & Helder Maria Romero Nakaya (Emory) Thomas Vazquez Hana Golding & Surender Khurana (FDA) Giuseppe del Guidice Richard Riley (Novartis) NIH-NIA, R37 AG023717 (BBB) Mike Antoni NIH-NIA, R01 AG032576 (BBB)NIH- Suzanne Lechner NIAID, R21 AI096446 (BBB+DF) FL Bankhead Coley Cancer Res Prog. (Antoni-Blomberg), 6/1/2016-5/31/2021 NIH (Penedo) NCI R01 CA206456 (collab. With Antoni and All the subjects! Northwestern) 7/01/2016 – 06/30/2021 OUTLINE - Introduction to Aging and Immune defects - Summary of our previous results for Influenza vaccine responses Biomarkers to predict the response: Sw Mem B, AID, low TNF-α - Measures of inflammation/obesity and B cell response - Conclusions, future directions Aging Immune System - 1 • In both mice and humans: • Decline in T cell (cellular) functions: – Thymus atrophy (involution) – Decline in T cell functions such as frequency of CD4+ T cells and mitogen activation Aging Immune System - 2 • In both mice and humans: • Decline in B cell (antibody) functions: – Diminished ability to generate high affinity protective antibody responses to immunization against infectious agents or experimental antigens.
    [Show full text]
  • Functional Capacities of Human Igm Memory B Cells in Early Inflammatory Responses and Secondary Germinal Center Reactions
    Functional capacities of human IgM memory B cells in early inflammatory responses and secondary germinal center reactions Marc Seiferta, Martina Przekopowitza, Sarah Taudiena, Anna Lolliesa, Viola Rongea, Britta Dreesa, Monika Lindemannb, Uwe Hillenc, Harald Englerd, Bernhard B. Singere, and Ralf Küppersa,1 aInstitute of Cell Biology (Cancer Research), bInstitute for Transfusion Medicine, cDepartment of Dermatology, dInstitute of Medical Psychology and Behavioural Immunobiology, and eInstitute of Anatomy, Medical Faculty, University of Duisburg-Essen, Essen 45122, Germany Edited* by Klaus Rajewsky, Max Delbruck Center for Molecular Medicine, Berlin, Germany, and approved December 30, 2014 (received for review August 22, 2014) The generation and functions of human peripheral blood (PB) IgM+ (BCRs) that are expressed on post-GC memory B cells or se- + + IgD CD27 B lymphocytes with somatically mutated IgV genes are creted by long-lived PCs (7). Egress of these cells to the lymph controversially discussed. We determined their differential gene node medullary chords, red pulp, or bone marrow is mediated expression to naive B cells and to IgM-only and IgG+ memory B by chemokine (C-X-C motif) ligand 12 (CXCL12) / chemokine cells. This analysis revealed a high similarity of IgM+(IgD+)CD27+ (C-X-C motif) receptor 4 (CXCR4) (8). + and IgG memory B cells but also pointed at distinct functional Specificity and memory represent the hallmarks of adaptive capacities of both subsets. In vitro analyses revealed a tendency immunity. Memory B cells are generated in adaptive immune of activated IgM+IgD+CD27+ B cells to migrate to B-cell follicles and responses and confer enhanced and improved reactivity against undergo germinal center (GC) B-cell differentiation, whereas acti- recurring antigen.
    [Show full text]